NCT05055908 Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
| NCT ID | NCT05055908 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Hunan Province Tumor Hospital |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 12,000 participants |
| Start Date | 2021-10-01 |
| Primary Completion | 2025-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 12,000 participants in total. It began in 2021-10-01 with a primary completion date of 2025-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
Eligibility Criteria
Inclusion Criteria: 1. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form. 2. Age ≥ 18 years. 3. Histologically or cytologically confirmed lung cancer. 4. Treated with Immune Checkpoint Inhibitors with or without chemotherapy. 6\. Predicted survival ≥ 12 weeks. 7. Adequate bone marrow hematopoiesis and organ function 8. Presence of measurable lesions according to RECIST 1.1. Exclusion Criteria: Any conditions can not match for the Inclusion Criteria, includign do not have the data to perform Adverse Events evalutation.
Contact & Investigator
Yongchang Zhang, MD
PRINCIPAL INVESTIGATOR
Hunan Cancer Hospital
Frequently Asked Questions
Who can join the NCT05055908 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05055908 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 12,000 participants.
Is NCT05055908 currently recruiting?
Yes, NCT05055908 is actively recruiting participants. Contact the research team at zhangyongchang@csu.edu.cn for enrollment information.
Where is the NCT05055908 trial being conducted?
This trial is being conducted at Changsha, China.
Who is sponsoring the NCT05055908 clinical trial?
NCT05055908 is sponsored by Hunan Province Tumor Hospital. The principal investigator is Yongchang Zhang, MD at Hunan Cancer Hospital. The trial plans to enroll 12,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.